PIRS
- Pieris Pharmaceuticals, Inc.
()
Overview
Company Summary
Pieris Pharmaceuticals, Inc. (PIRS) is a biotechnology company that focuses on the development and commercialization of novel therapeutic proteins to address various diseases, particularly in the field of oncology.
The main approach that sets Pieris Pharmaceuticals apart is the use of Anticalin proteins, a proprietary class of therapeutic proteins. Anticalin proteins are specifically engineered to bind to disease targets with high affinity and selectivity, enabling targeted therapy delivery. These proteins offer advantages over traditional antibodies, including improved tissue penetration, fast clearance from non-target tissues, and reduced immunogenicity.
Pieris Pharmaceuticals has developed a platform technology called Anticalin technology, which allows the creation of a diverse library of these therapeutic proteins. This library can be mined to discover lead candidates that can be further optimized and developed into drug candidates.
The company has focused its research and development efforts on the treatment of cancer, respiratory diseases, and other severe disorders. They collaborate with strategic partners in the pharmaceutical industry to advance their drug candidates through preclinical and clinical development stages, ultimately aiming for regulatory approval and commercialization.
Pieris Pharmaceuticals also actively seeks partnerships and collaborations with other biopharmaceutical companies to leverage their technology and expand their product pipeline. By partnering with established pharmaceutical companies, they can access additional resources, expertise, and potentially accelerate the development and commercialization of their drug candidates.
The ultimate goal of Pieris Pharmaceuticals is to develop innovative therapeutic solutions that can improve the lives of patients facing serious medical conditions. Through their unique Anticalin platform and strategic collaborations, they strive to advance the understanding and treatment of various diseases, particularly in the field of oncology.